WallStreetZenWallStreetZen

NASDAQ: RAPP
Rapport Therapeutics Inc Stock Ownership - Who owns Rapport Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Rapport Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Krishnaswamy YeleswaramChief Development Officer2026-04-1720,225$39.99
$808.84kSell
Krishnaswamy YeleswaramChief Development Officer2026-04-1410,200$35.08
$357.80kSell
Krishnaswamy YeleswaramChief Development Officer2026-04-139,165$34.97
$320.54kSell
Krishnaswamy YeleswaramChief Development Officer2026-04-10500$34.98
$17.49kSell
Krishnaswamy YeleswaramChief Development Officer2026-04-08360$34.90
$12.56kSell
Cheryl GaultChief Operating Officer2026-03-302,839$28.55
$81.06kSell
Cheryl GaultChief Operating Officer2026-03-307,161$28.04
$200.79kSell
Krishnaswamy YeleswaramChief Development Officer2026-03-2510,115$29.99
$303.36kSell
Cheryl GaultChief Operating Officer2026-03-052,014$28.93
$58.27kSell
David BredtChief Scientific Officer2026-02-196,000$1.80
$10.80kBuy

1 of 7

RAPP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RAPP insiders and whales buy or sell their stock.

RAPP Shareholders

What type of owners hold Rapport Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Third Rock Ventures V LP16.96%8,104,451$301.00MInsider
Trv GP V LLC14.93%7,135,233$265.00MInstitution
Fmr LLC14.88%7,111,865$264.13MInstitution
Arch Venture Partners XII LLC7.80%3,728,738$138.49MInsider
Arch Venture Management LLC7.80%3,728,738$138.49MInstitution
Capital International Investors7.12%3,402,529$126.37MInstitution
Cormorant Asset Management LP6.33%3,027,521$112.44MInstitution
Goldman Sachs Group Inc6.28%3,001,879$111.49MInstitution
Goldman Sachs Group Inc 16.28%3,001,879$111.49MInstitution
Blackrock Inc5.09%2,431,862$90.32MInstitution

1 of 3

RAPP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RAPP76.10%23.90%Net SellingNet Selling
NUVB57.01%42.99%Net BuyingNet Buying
ATAI15.24%32.96%Net BuyingNet Buying
INVA60.21%39.79%Net BuyingNet Selling
TSHA89.47%10.53%Net SellingNet Selling
View Top Biotech Stocks

Rapport Therapeutics Stock Ownership FAQ

Who owns Rapport Therapeutics?

Rapport Therapeutics (NASDAQ: RAPP) is owned by 106.89% institutional shareholders, 33.57% Rapport Therapeutics insiders, and 0.00% retail investors. Third Rock Ventures V LP is the largest individual Rapport Therapeutics shareholder, owning 8.10M shares representing 16.96% of the company. Third Rock Ventures V LP's Rapport Therapeutics shares are currently valued at $299.46M.

If you're new to stock investing, here's how to buy Rapport Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.